Published in Cancer Weekly, July 20th, 2004
According to a study from the University of Chicago, "CD43 is a large heavily glycosylated protein highly expressed on T cells and actively excluded from the immunological synapse through interactions with ezrin-radixin-moesin proteins. Due to its size and charge, it has been proposed that the CD43 ectodomain acts as a physical barrier to T cell-APC interactions."
"We have addressed this hypothesis by studying the effect of reconstituting CD43 mutants into the hyperproliferative CD43-/- T cells. Reintroduction of full-length CD43 reversed the CD43-/- T cell...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.